Literature DB >> 14526393

Intrahepatic cholestasis after liver transplantation.

Ziv Ben-Ari1, Orit Pappo, Eytan Mor.   

Abstract

Cholestasis is a common sequela of liver transplantation. Although the majority of cases remain subclinical, severe cholestasis may be associated with irreversible liver damage, requiring retransplantation. Therefore, it is essential that clinicians be able to identify and treat the syndromes associated with cholestasis. In this review, we consider causes of intrahepatic cholestasis. These may be categorized by time of occurrence, namely, within 6 months of liver transplantation (early) and thereafter (late), although there may be an overlap in their causes. The causes of intrahepatic cholestasis include ischemia/reperfusion injury, bacterial infection, acute cellular rejection, cytomegalovirus infection, small-for-size graft, drugs for hepatotoxicity, intrahepatic biliary strictures, chronic rejection, hepatic artery thrombosis, ABO blood group incompatibility, and recurrent disease. The mechanisms of cholestasis in each category and the clinical presentation, diagnosis, treatment, and outcome are discussed in detail.

Entities:  

Mesh:

Year:  2003        PMID: 14526393     DOI: 10.1053/jlts.2003.50212

Source DB:  PubMed          Journal:  Liver Transpl        ISSN: 1527-6465            Impact factor:   5.799


  17 in total

1.  Intermittent ischaemia maintains function after ischaemia reperfusion in steatotic livers.

Authors:  Mathilde Steenks; Mark C P M van Baal; Vincent B Nieuwenhuijs; Menno T de Bruijn; Marc Schiesser; Mike H Teo; Tom Callahan; Rob T A Padbury; Greg J Barritt
Journal:  HPB (Oxford)       Date:  2010-05       Impact factor: 3.647

2.  Frequency, clinical presentation, and outcomes of drug-induced liver injury after liver transplantation.

Authors:  Stepan Sembera; Craig Lammert; Jayant A Talwalkar; Schuyler O Sanderson; John J Poterucha; J Eileen Hay; Russell H Wiesner; Gregory J Gores; Charles B Rosen; Julie K Heimbach; Michael R Charlton
Journal:  Liver Transpl       Date:  2012-07       Impact factor: 5.799

3.  Hepatobiliary Quiz Answers-17 (2016).

Authors:  Sahaj Rathi; Radha K Dhiman
Journal:  J Clin Exp Hepatol       Date:  2016-05-04

4.  Taurocholic acid prevents biliary damage induced by hepatic artery ligation in cholestatic rats.

Authors:  Shannon Glaser; Paolo Onori; Eugenio Gaudio; Yoshiyuki Ueno; Luigi Pannarale; Antonio Franchitto; Heather Francis; Romina Mancinelli; Guido Carpino; Julie Venter; Mellanie White; Shelley Kopriva; Antonella Vetuschi; Roberta Sferra; Gianfranco Alpini
Journal:  Dig Liver Dis       Date:  2010-03-20       Impact factor: 4.088

Review 5.  Cholesterol metabolism in cholestatic liver disease and liver transplantation: From molecular mechanisms to clinical implications.

Authors:  Katriina Nemes; Fredrik Åberg; Helena Gylling; Helena Isoniemi
Journal:  World J Hepatol       Date:  2016-08-08

Review 6.  Clinical significance of donor-specific human leukocyte antigen antibodies in liver transplantation.

Authors:  Antonio Cuadrado; David San Segundo; Marcos López-Hoyos; Javier Crespo; Emilio Fábrega
Journal:  World J Gastroenterol       Date:  2015-10-21       Impact factor: 5.742

Review 7.  Role of matrix metalloproteinases in cholestasis and hepatic ischemia/reperfusion injury: A review.

Authors:  Giuseppina Palladini; Andrea Ferrigno; Plinio Richelmi; Stefano Perlini; Mariapia Vairetti
Journal:  World J Gastroenterol       Date:  2015-11-14       Impact factor: 5.742

8.  Ischemic preconditioning and intermittent ischemia preserve bile flow in a rat model of ischemia/reperfusion injury.

Authors:  Vincent B Nieuwenhuijs; Menno T de Bruijn; Marc Schiesser; Arthur Morphett; Robert T A Padbury; Greg J Barritt
Journal:  Dig Dis Sci       Date:  2007-07-31       Impact factor: 3.199

9.  Pharmacokinetics of Dexmedetomidine in Infants and Children After Orthotopic Liver Transplantation.

Authors:  Mihaela A Damian; Gregory B Hammer; Mohammed H Elkomy; Adam Frymoyer; David R Drover; Felice Su
Journal:  Anesth Analg       Date:  2020-01       Impact factor: 5.108

10.  Chemokine Receptor-5Delta32 Mutation is No Risk Factor for Ischemic-Type Biliary Lesion in Liver Transplantation.

Authors:  Christoph Heidenhain; Gero Puhl; Christian Moench; Anja Lautem; Peter Neuhaus
Journal:  J Transplant       Date:  2009-03-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.